Loading patent…
AssigneeCorcept Therapeutics, Inc.
InventorsAndreas Moraitis, Joseph Custodio
Estimating the term…
Applicant discloses methods, uses, and compositions of heteroaryl ketone fused azadecalin compounds for treating patients suffering from Cushing's syndrome or Cushing's Disease (collectively “CS”) without causing significant QT interval prolongation (e.g., the QT interval following administration differs by no more than about 10 milliseconds from the baseline QT interval). Therapeutic amounts of the heteroaryl ketone fused azadecalin compounds may be between about 50 milligrams per day (mg/day) and up to about 500 mg/day, and in embodiments may be up to about 800 mg/day. The methods, uses, and compositions may reduce QT interval, and may be useful for treating QT prolongation in patients, including CS patients. The treatments may be oral treatments administered to a fasted patient, or to a fed patient. The heteroaryl ketone fused azadecalin compounds may be administered with a meal. The heteroaryl ketone fused azadecalin compound may be relacorilant, which is (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, which has the structure:
A method of treating a patient suffering from Cushing's syndrome or Cushing's Disease (collectively “CS”) without significantly prolonging said patient's QT interval, where the QT interval is the duration of the time interval between the beginning of the QRS complex of the electrocardiogram (ECG) and the end of the T wave of the ECG, wherein a patient's QT interval is significantly prolonged if the QT interval is increased by more than 10 milliseconds (ms) from the patient's baseline QT interval,
A method of treating a patient suffering from Cushing's syndrome or Cushing's Disease (collectively “CS”) and suffering from prolonged QT interval, where the QT interval is the duration of the time interval between the beginning of the QRS complex of the electrocardiogram (ECG) and the end of the T wave of the ECG, and wherein a prolonged QT interval is a QT interval greater than about 450 ms in men or greater than about 460 ms in women,
A method of decreasing the QT interval in a patient with a prolonged QT interval, where the QT interval is the duration of the time interval between the beginning of the QRS complex of the electrocardiogram (ECG) and the end of the T wave of the ECG, and wherein a prolonged QT interval is a QT interval greater than about 450 ms in men or greater than about 460 ms in women,
A method of reducing the effect on QT interval in a patient receiving a drug known to prolong the QT interval of the electrocardiogram (ECG) in some patients, where the QT interval is the duration of the time interval between the beginning of the QRS complex of the ECG and the end of the T wave of the ECG, and wherein a prolonged QT interval is a QT interval greater than about 450 ms in men or greater than about 460 ms in women, the method comprising:
Dependencies are inferred from the claim text.